Novartis Ag

Other

Sandoz Gmbh

Novartis Pharma Gmbh

Philipp Lehr

Andreas Billich

Hubert Gstach

Jose M Carballido Herrera

Herbert Jaksche

Gudrun Werner

Anthony Winiski

Peter Ettmayer

Erwin Paul Schreiner

Dieter Scholz

Amarylla Horvath

Peter Nussbaumer

Brigitte Charpiot

The present invention relates 3,4-dihydro-benzo[e][1,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C)alkyl, (C)cycloalkyl, (C)cycloalkyl(C)alkyl, (C)aryl or (C)aryl(C)alkyl and their use as pharmaceuticals.

3,4-dihydro-benzo[e][1,3]oxazin-2-ones

N-(benzenesulphonyl)-2,3-dihydro-1H-indols, wherein the indol is substituted by cyano, carboxy or alkylcarbonyloxy and their use as therapeutical agents.

N-arylsulfonyl-2,3-dihydro-1H-indoles and the use thereof as CCR9 inhibitors

Compounds of formula I, wherein one of Rand Ris thienyl which is substituted by halogen and the other of Rand Ris substituted phenyl, wherein the substituents are as defined in the claims, with the proviso that the phenyl group is substituted by at least a cyano, carboxy or ()alkyloxycarbonyl group, are inhibitors of CCR9 activity and useful for therapeutic treatment. 

Inhibitors of CCR9 activity

A compound of formula wherein Ris haloalkyl, alkenyl, phenyl, thienyl, pyridine, benzthiazolyl, chromanyl (1,2-dihydrobenzopyranyl) or (C)aryl, and Ror Rindependently of each other are substituted (C)cycloalkyl, a substituted bridged cycloalkyl system, substituted piperidine, substituted tetrahydropyridine, or a substituted bridged heterocyclic system, useful as a pharmaceutical.

Acylsulfonamides as inhibitors of steroid sulfatase

Piperazinyl- or piperidinylamine-sulfamic acid amides and their use for the manufacture of a medicament in diseases mediated by the action of steriod sulfatase.

Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase

3,4-dihydro-benzo[e][1,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C)cycloalkyl, (C)alkyl(C)cycloalkyl, (C)aryl or (C)aryl(C)alkyl and their use as pharmaceuticals.

MIF-inhibitors

The invention relates to compounds of formula I ##STR1## wherein the substituents have various significances. They can be prepared by conventional methods, e.g. coupling, substitution, deprotection or protection reactions. They possess interesting pharmacological properties and are thus indicated for use in the treatment of retroviral infections, particularly as HIV proteinase inhibitors.

Growing community of inventors

Vienna, Austria

Philipp Lehr